*Repeat administration every 4 to 8 weeks as needed in the individual patient.1
References:
1. Michels, G. M., Ramsey, D. S., Walsh, K. F., Martinon, O. M., Mahabir, S. P., Hoevers, J. D., Walters, R. R. and Dunham, S. A. (2016), A blinded, randomized, placebo controlled, dose determination trial of lokivetmab (ZTS-00103289), a caninized, anti-canine IL-31 monoclonal antibody in client owned dogs with atopic dermatitis. Vet Dermatol. doi:10.1111/vde.12376